Insights on Clinical Trials

  1. AI Tools In Informed Consent: What Sponsors Need To Know About Risk 8/1/2026

    AI tools carry different risks. See how they can impact participant communications, where bias and inaccuracies emerge, and why human review is critical to protecting study integrity.

  2. Demonstrating The Value Of Investigational Drug Services Through Time-Based Metrics 7/29/2026

    Learn how adopting time-based metrics helps research teams accurately track workload, optimize staffing, and justify trial budgets.

  3. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  4. Drug Development Plan Explained: DPP Templates And Examples 7/27/2026

    Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.

  5. The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue 7/21/2026

    AI can close CAR-T’s access gap by replacing fragmented community delivery handoffs with automated orchestration across referral, reimbursement, logistics, and monitoring.

  6. Next-Generation ADC Trials – Turning Complexity Into Execution 7/20/2026

    As ADC science advances, operational strategy becomes critical. Learn how smarter protocol design, real-time monitoring and collaborative execution can accelerate next-generation ADC trials.

  7. Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/20/2026

    CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

  8. It's A Mad Men World For IRB Review Of Clinical Trial Advertisements 7/13/2026

    Modern digital tools and AI have transformed clinical trial recruitment, outpacing decades-old regulations. Discover how to apply core ethical principles to protect participant privacy and equity.

  9. Why CGT Access Strategy Must Go Beyond Academic Medical Centers 7/7/2026

    Academic medical centers built the foundation for CGT delivery, but their reach has a ceiling. Closing the access gap means rethinking how these therapies move through community hospital networks at scale.

  10. The Lasting Impact Of Treatment Gaps In ARG1-D 6/26/2026

    A patient story from ARG1-D reveals how even brief treatment interruptions can trigger irreversible decline and why continuity of care must remain a priority in rare disease research.